RCT in 505 patients with high-risk locally advanced rectal cancer: adding oxaliplatin to capecitabine chemoradiation did not improve 3-year disease-free survival (primary end point) or overall survival; marked tumour regression was more frequent (58.6% vs 46.8%).
RCTn = 505
Zhou et al. CapeOX Versus Capecitabine in Neoadjuvant Chemoradiation for High-Risk Locally Advanced Rectal Cancer: Long-Term Results From the MONT-R Randomized Controlled Trial